Targeted Therapy for HM1.24 (CD317)‎ on Multiple Myeloma Cells

Abstract EN

Multiple myeloma (MM) still remains an incurable disease, at least because of the existence of cell-adhesion mediated drug-resistant MM cells and/or continuous recruitment of presumed MM cancer stem cell-like cells (CSCs).

As a new alternative treatment modality, immunological approaches using monoclonal antibodies (mAbs) and/or cytotoxic T lymphocytes (CTLs) are now attracting much attention as a novel strategy attacking MM cells.

We have identified that HM1.24 [also known as bone marrow stromal cell antigen 2 (BST2) or CD317] is overexpressed on not only mature MM cells but also MM CSCs.

We then have developed a humanized mAb to HM1.24 and defucosylated version of the mAb to adapt to clinical practice.

Moreover, we have successfully induced HM1.24-specific CTLs against MM cells.

The combination of these innovative therapeutic modalities may likely exert an anti-MM activity by evading the drug resistance mechanism and eliminating presumed CSCs in MM.